Pre-Exposure Prophylaxis

LOS ANGELES —In this video from IDWeek, Vani Vannappagari, MBBS, PhD, MPH, global head of epidemiology and real-world evidence at ViiV Healthcare, discusses study findings demonstrating the effectiveness of cabotegravir for HIV prevention.

LOS ANGELES — Lenacapavir, the twice-yearly injectable HIV drug, could potentially transform HIV prevention if it is approved as PrEP, research has shown.

Access to pre-exposure prophylaxis remains insufficient, especially among Black, Hispanic and Medicare-insured populations, results of an analysis presented at IDWeek suggested.

LIMA, Peru — In a finding described as “reassuring,” researchers detected no interaction between the long-acting HIV prevention drug cabotegravir and hormonal contraceptives among women enrolled in a large trial.

Twice-yearly injectable lenacapavir for HIV prevention reduced HIV infections by 96% compared with background HIV incidence and demonstrated superiority over a once-daily pill for PrEP in a phase 3 trial, Gilead Sciences announced Thursday.

Testing HIV PrEP users for STIs every 6 months did not increase the risk for STIs compared with testing them every 3 months and could reduce the cost of PrEP programs, according to a study.

A 60-year-old man in Germany became the seventh person to be considered potentially cured of HIV after receiving a stem cell transplant from a person with a genetic mutation that prevents infection.

Long-acting injectable PrEP is feasible and acceptable to both men and women, according to a study presented at the AIDS 2024 meeting in Munich.

Lenacapavir, an injectable antiretroviral drug approved by the FDA for HIV treatment, prevented 100% of new HIV infections among women in a phase 3 trial in Africa, demonstrating its efficacy as PrEP, Gilead Sciences said.